Piracetam for Treatment of Cocaine Addiction - 3
This study has been completed.
Information provided by (Responsible Party):
Kyle Kampman, University of Pennsylvania
First received: September 20, 1999
Last updated: December 12, 2013
Last verified: December 2013
The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program.
||Primary Purpose: Treatment
||Piracetam for Treatment of Cocaine Addiction
Primary Outcome Measures:
- Pulse, blood pressure
- Adverse effects
- High, anxiety, withdrawal
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 1997 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||21 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Please contact site for information.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000198
|University of Pennsylvania
|Philadelphia, Pennsylvania, United States, 19104 6178 |
University of Pennsylvania
||Kyle Kampman, M.D.
||University of Pennsylvania
No publications provided
||Kyle Kampman, Principal Investigator, University of Pennsylvania
History of Changes
|Other Study ID Numbers:
||NIDA-00238-3, K20DA000238, K02-00238-3
|Study First Received:
||September 20, 1999
||December 12, 2013
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 28, 2014
Physiological Effects of Drugs
Central Nervous System Agents